ArticleMolecular therapy : the journal of the American Society of Gene Therapy2012
Inflammation, apoptosis, and necrosis induced by neoadjuvant fas ligand gene therapy improves survival of dogs with spontaneous bone cancer.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- The immunotherapy of canine osteosarcoma: a historical and systematic review.Journal of veterinary internal medicinePooled it
- Distinct mechanisms of PTEN inactivation in dogs and humans highlight convergent molecular events that drive cell division in the pathogenesis of osteosarcoma.Cancer genetics · 2023Article
- Exploring the association of intratumoral immune cell infiltrates with histopathologic grade in canine mast cell tumors.Research in veterinary science · 2022Article
- Article
- Safety evaluation of the canine osteosarcoma vaccine, live Listeria vector.Veterinary and comparative oncology · 2021Article
- Natural Killer and T Cell Infiltration in Canine Osteosarcoma: Clinical Implications and Translational Relevance.Frontiers in veterinary science · 2021Review
- Recent and current clinical trials in canine appendicular osteosarcoma.The Canadian veterinary journal = La revue veterinaire canadienne · 2020Review
- Article
- Osteosarcoma in the Post Genome Era: Preclinical Models and Approaches to Identify Tractable Therapeutic Targets.Current osteoporosis reports · 2019Review
- Metastatic immune infiltrates correlate with those of the primary tumour in canine osteosarcoma.Veterinary and comparative oncology · 2019Article
- Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma.Veterinary and comparative oncology · 2019Article
- Comparative Approach to the Temporo-Spatial Organization of the Tumor Microenvironment.Frontiers in oncology · 2019Review
- Clonal cooperativity in heterogenous cancers.Seminars in cell & developmental biology · 2017Review
- A phase I clinical study to evaluate safety of orally administered, genetically engineeredVeterinary medicine and science · 2016Article
- Defining the Value of a Comparative Approach to Cancer Drug Development.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Review
- Understanding the Osteosarcoma Pathobiology: A Comparative Oncology Approach.Veterinary sciences · 2016Review
- Progress in Adaptive Immunotherapy for Cancer in Companion Animals: Success on the Path to a Cure.Veterinary sciences · 2015Article
- Aberrant Retinoblastoma (RB)-E2F Transcriptional Regulation Defines Molecular Phenotypes of Osteosarcoma.The Journal of biological chemistry · 2015Article
- Mesenchymal stromal cells inhibit murine syngeneic anti-tumor immune responses by attenuating inflammation and reorganizing the tumor microenvironment.Cancer immunology, immunotherapy : CII · 2015Article
- Interleukin-8 promotes canine hemangiosarcoma growth by regulating the tumor microenvironment.Experimental cell research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 1 country.
Funding
Abstract
Fas ligand (FasL) gene therapy for cancer has shown promise in rodents; however, its efficacy in higher mammals remains unknown. Here, we used intratumoral FasL gene therapy delivered in an adenovirus vector (Ad-FasL) as neoadjuvant to standard of care in 56 dogs with osteosarcoma. Tumors from treated dogs had greater inflammation, necrosis, apoptosis, and fibrosis at day 10 (amputation) compared to pretreatment biopsies or to tumors from dogs that did not receive Ad-FasL. Survival improvement was apparent in dogs with inflammation or lymphocyte-infiltration scores >1 (in a 3-point scale), as well as in dogs that had apoptosis scores in the top 50th percentile (determined by cleaved caspase-3). Survival was no different than that expected from standard of care alone in dogs with inflammation scores ≤1 or apoptosis scores in the bottom 50th percentile. Reduced Fas expression by tumor cells was associated with prognostically advantageous inflammation, and this was seen only in dogs that received Ad-FasL. Together, the data suggest that Ad-FasL gene therapy improves survival in a subset of large animals with naturally occurring tumors, and that at least in some tumor types like osteosarcoma, it is most effective when tumor cells fail to express Fas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.